Contributor Cindy H. Dubin presents how today’s leading analytical testing service providers are taking advantage of AI and other types of automation and innovative technologies.
EXECUTIVE INTERVIEW – How Resilience Is Bringing Forward Thinking to Disrupt the Biomanufacturing Landscape to Increase Access to Medicines
Syed T. Husain, Chief Commercial Officer of Resilience, discusses how the company became an industry-leading service provider in less than 4 years.
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
SPECIAL ROUNDTABLE – Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024
Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.
DRUG DISCOVERY – Overcoming Traditional Challenges: Innovative Chemoproteomics Strategies to Revolutionize Drug Discovery
Ping Cao, PhD, and Irene Yuan believe their chemoproteomic platform offers a distinct advantage by enabling the simultaneous exploration of the entire proteome, setting it apart from other drug discovery technologies that typically focus on individual targets.
Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.
DRUG DEVELOPMENT – Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
SUPPLY CHAIN VISIBILITY – New Tracking Technologies Driving Improvements to Reduce Drug Shortages, Expedite Recalls, Protect & Inform Patients
Tracy Nasarenko says new technologies are being leveraged along with industry standards to enable full visibility across the entire supply chain, tracking products all the way from manufacturer to end user.
Emmanuel Belabe says many CROs believe they’ve reached a breaking point as they work to keep up with rising case volumes, data complexities, and changing regulations. To combat these pressures, CROs need access to modern pharmacovigilance (PV) automation that promotes flexibility, scalability, efficiency, and cost-effectiveness.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
EXECUTIVE INTERVIEW – Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.